iX Biopharma

iX Biopharma secures Israel patent for WaferiX - THE EDGE SINGAPORE

Company in the news

iX Biopharma secures Israel patent for WaferiX

iX Biopharma has been granted a patent in Israel for its WaferiX drug delivery technology.

iX Biopharma receives notice of allowance of WaferiX patent from US

Company in the news

iX Biopharma receives notice of allowance of WaferiX patent from US

iX Biopharma has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for its patent application on Tuesday (August 4).

Company in the news

iX Biopharma inks supply agreement with Cannatrek to supply medicinal cannabis wafer in Australia

SINGAPORE (Apr 29): iX Biopharma has entered into a supply agreement with Cannatrek, a medical cannabis enterprise, to supply Xativa, the world’s first freeze-dried sublingual medicinal cannabis wa

ix biopharma

Company in the news

iX Biopharma enters China market with licensing agreement for erectile dysfunction drug

SINGAPORE (Apr 27): iX Biopharma has entered into a 10-year licensing agreement with Yiling Pharmaceutical in China for the licensing, supply, and distribution of Wafesil, a fast-dissolvi

Company in the news

iX Biopharma secures licence to manufacture cannabis in Australia

SINGAPORE (Dec 5): iX Biopharma has been awarded a cannabis manufacture license from the Australian Office of Drug Control to manufacture and supply extracts and tinctures of cannabis and cannabis

Results

iX Biopharma back in the black with 3Q earnings of $7.8 mil on one-off disposal gain

SINGAPORE (May 9): iX Biopharma announced 3Q19 earnings of $7.8 million, compared to a loss of $3.9 million in 3Q18, due to a one-off gain from the disposal of a subsidiary.

Update

iX Biopharma disposes of Australian lab testing business for $12 mil after 2Q losses

SINGAPORE (Feb 18): iX Biopharma is selling Chemical Analysis, its laboratory testing business in Australia, to Eurofins Australia New Zealand Holding for A$12.5 million ($12 million).  

Results

iX Biopharma 2Q losses widen 11% to $3.6 mil

SINGAPORE (Feb 12): Specialty pharmaceutical and nutraceutical firm iX Biopharma has reported a net loss of $3.6 million in 2Q19, an increase of 11% compared to a net loss of $3.2 million in 2Q18.

In print this week

Bringing home the bacon

SINGAPORE (Feb 1): The Edge Singapore has assembled the annual portfolio of 10 stocks, done in conjunction with the Lunar New Year.

iXBiopharma's Wafesil granted regulatory approval for treatment of male erectile dysfunction in Australia

SINGAPORE (June 19): iX Biopharma says the Australia’s regulatory authority, Therapeutic Goods Administration (TGA), has given the go-ahead for the use of Wafesil to treat of male erectile dysfunct

×